SRSF2 and acute myeloid leukemia: H3K27me3 is of prognostic significance in our AML cohort with worse outcomes overall and in particular subgroups, i.e. intermediate and unfavorable AML, IDH1, ASXL1, BCOR, U2AF1 and SRSF2 mutated patients.